Loading
A phase 3 trial of ASP-1929 Photoimmunotherapy in head and neck squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy is a phase 3 interventional study registered as NCT03769506 by Rakuten Medical, Inc., with 135 participants enrolled, started 2019-05-09 and due to reach its primary completion in 2025-12. Interventions recorded: ASP-1929 Photoimmunotherapy and Physician's Choice SOC.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rakuten Medical, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/